FOXO1 and ovarian carcinoma: In paclitaxel-resistant ovarian cancer cells, Trx1 is involved in overcoming drug toxicity by binding to the FOXO1 transcription factor, inducing its nuclear translocation, and enhancing FOXO1 transcriptional activity (Wang et al., 2015).